Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Fluorothiazinone Infusion in Healthy Volunteers
NCT07184606Phase 1Not yet recruiting
- Start
- Sep 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of Fluorothiazinone in bacterial infection and complicated urinary tract infection (cUTI) (6 arms). Primary endpoint: Occurrence of adverse events (AE) at 7 days. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
Fluorothiazinone
03
Conditions
bacterial infectioncomplicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on NCT07184606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07184606.